Daniel M Fountain1, Dominic Allen1, Alexis J Joannides1, Dipankar Nandi1, Thomas Santarius1, Aswin Chari1. 1. Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK (D.M.F., A.J.J., T.S.); Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (D.M.F, A.J.J, T.S); Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK (D.A, D.N, A.C); Department of Neurosurgery, Imperial College Healthcare NHS Trust, London, UK (D.A, D.N, A.C).
Abstract
BACKGROUND: Patient-reported health-related quality of life (HRQoL) analysis can provide important information for managing the balance between treatment benefits and treatment-related adverse effects on quality of life (QoL). This systematic review sought to identify the range of HRQoL measures used for patients with diffuse hemispheric WHO grade II glioma (DLGG) and assess the quality of HRQoL reporting. METHODS: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases were searched for full-text English articles reporting HRQoL outcomes in adult patients with DLGG. RESULTS: Eleven different QoL measures were used across the 26 included studies, none of which has been validated in patients with DLGG. Heterogeneity of study design prevented pooled analysis of data investigating the effect of interventions or establishing long-term HRQoL. Low rates of participation at baseline (mean: 64.0%) and high rates of subsequent dropout (2.1% per month) were identified. Five studies gave statistical methods to deal with missing data or provided evidence of clinical significance of HRQoL results. CONCLUSIONS: The results demonstrate a paucity and heterogeneity of reporting of HRQoL in the DLGG literature, highlighting the need for a standardized assessment schedule and set of validated quality-of-life measures for future studies.
BACKGROUND:Patient-reported health-related quality of life (HRQoL) analysis can provide important information for managing the balance between treatment benefits and treatment-related adverse effects on quality of life (QoL). This systematic review sought to identify the range of HRQoL measures used for patients with diffuse hemispheric WHO grade II glioma (DLGG) and assess the quality of HRQoL reporting. METHODS: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases were searched for full-text English articles reporting HRQoL outcomes in adult patients with DLGG. RESULTS: Eleven different QoL measures were used across the 26 included studies, none of which has been validated in patients with DLGG. Heterogeneity of study design prevented pooled analysis of data investigating the effect of interventions or establishing long-term HRQoL. Low rates of participation at baseline (mean: 64.0%) and high rates of subsequent dropout (2.1% per month) were identified. Five studies gave statistical methods to deal with missing data or provided evidence of clinical significance of HRQoL results. CONCLUSIONS: The results demonstrate a paucity and heterogeneity of reporting of HRQoL in the DLGG literature, highlighting the need for a standardized assessment schedule and set of validated quality-of-life measures for future studies.
Authors: Cagdas Yavas; Faruk Zorlu; Gokhan Ozyigit; Murat Gurkaynak; Guler Yavas; Deniz Yuce; Mustafa Cengiz; Ferah Yildiz; Fadil Akyol Journal: Support Care Cancer Date: 2011-10-08 Impact factor: 3.603
Authors: Astrid Erharter; Johannes Giesinger; Georg Kemmler; Gabriele Schauer-Maurer; Guenter Stockhammer; Armin Muigg; Markus Hutterer; Gerhard Rumpold; Barbara Sperner-Unterweger; Bernhard Holzner Journal: J Pain Symptom Manage Date: 2010-02 Impact factor: 3.612
Authors: M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs Journal: Lancet Oncol Date: 2011-04-05 Impact factor: 41.316
Authors: G M Kiebert; D Curran; N K Aaronson; M Bolla; J Menten; E H Rutten; E Nordman; M E Silvestre; M Pierart; A B Karim Journal: Eur J Cancer Date: 1998-11 Impact factor: 9.162
Authors: A Pace; A Vidiri; E Galiè; M Carosi; S Telera; A M Cianciulli; P Canalini; D Giannarelli; B Jandolo; C M Carapella Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: Ben Rimmer; Iakov Bolnykh; Lizzie Dutton; Joanne Lewis; Richéal Burns; Pamela Gallagher; Sophie Williams; Vera Araújo-Soares; Fiona Menger; Linda Sharp Journal: Qual Life Res Date: 2022-08-06 Impact factor: 3.440
Authors: Daniel M Fountain; Andrew Bryant; Damiano Giuseppe Barone; Mueez Waqar; Michael G Hart; Helen Bulbeck; Ashleigh Kernohan; Colin Watts; Michael D Jenkinson Journal: Cochrane Database Syst Rev Date: 2021-01-04
Authors: Rocío Fernández-Méndez; Rebecca J Rastall; William A Sage; Ingela Oberg; Gemma Bullen; Amy Louise Charge; Anna Crofton; Thomas Santarius; Colin Watts; Stephen J Price; Andrew Brodbelt; Alexis J Joannides Journal: Neurooncol Pract Date: 2018-10-17
Authors: Amélie Darlix; Emmanuel Mandonnet; Christian F Freyschlag; Daniel Pinggera; Marie-Therese Forster; Martin Voss; Joachim Steinbach; Carmel Loughrey; John Goodden; Giuseppe Banna; Concetta Di Blasi; Nicolas Foroglou; Andreas F Hottinger; Marie-Hélène Baron; Johan Pallud; Hugues Duffau; Geert-Jan Rutten; Fabien Almairac; Denys Fontaine; Luc Taillandier; Catarina Pessanha Viegas; Luisa Albuquerque; Gord von Campe; Tadeja Urbanic-Purkart; Marie Blonski Journal: Neurooncol Pract Date: 2018-12-13
Authors: Mirjam Renovanz; Anne-Katrin Hickmann; Minou Nadji-Ohl; Naureen Keric; Elke Weimann; Christian Rainer Wirtz; Susanne Singer; Florian Ringel; Jan Coburger Journal: Support Care Cancer Date: 2020-02-14 Impact factor: 3.603